Search results
PROMOTED
Author(s):
Jasper J Brugts
Added:
1 month ago
Watch our video collection following the late-breaking science sessions from the ESC Heart Failure Association's 2025 congress. Our Expert Interviews provide insights on the hottest data and key take-home messages from the most influential trials.
View more
ESC HF 2025 Late-Breaking Science Collection
Video Series
Start date:
May 09, 2026
End date:
May 12, 2026
ESC Heart Failure Congress 2026 is set to take place from 9th to 12th May in Barcelona, Spain. The exact location will be revealed closer to the date.
View more
Author(s):
Mohammed El-Sheikh
Added:
3 weeks ago
In this short interview, Dr Mohammed El-Sheikh discusses the key findings and clinical relevance of his recently published article, “Associations of Obesity and Prognostic Nutritional Index on 1-Year Mortality in Patients with Acute Heart Failure.”
View more
Author(s):
Ovidiu Chioncel
Added:
1 month ago
In this short video, Dr Ovidiu Chioncel shares why acute heart failure remains a critical area of focus in cardiology, highlighting the urgent need for improved strategies in diagnosis and management.This conversation sets the stage for his upcoming Special Focus in Cardiac Failure Review (Impact Factor: 4.2) in 2026, which will explore this topic further.
View more
Author(s):
Marat Fudim
Added:
1 month ago
In this short interview, Dr Marat Fudim offers a preview of his upcoming manuscript, set to appear in the Sleep Disordered Breathing in Heart Failure special focus collection in Cardiac Failure Review. He discusses the evolving role of home sleep testing in diagnosing sleep apnea in patients with heart failure, addressing key considerations in clinical workflows and patient selection.Watch now to…
View more
Author(s):
Renzo Laborante
,
Attilio Restivo
,
Daniela Mele
,
et al
Added:
1 month ago
Background of Heart Failure
Author(s):
Raluca Ibănescu
,
Diana-Alexandra Mîțu
,
Iacob-Daniel Goje
,
et al
Added:
3 months ago
Article
Author(s):
Stephen J Greene
Added:
1 month ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an…
View more
Author(s):
Karol Mirkowski
,
Ercole Vellone
,
Bernadetta Żółkowska
,
et al
Added:
4 months ago
Author(s):
Antonio Luca Maria Parlati
,
Cristina Madaudo
,
Vincenzo Nuzzi
,
et al
Added:
5 months ago